<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id><journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id><journal-title-group><journal-title>Anais Brasileiros de Dermatologia</journal-title></journal-title-group><issn pub-type="ppub">0365-0596</issn><issn pub-type="epub">1806-4841</issn><publisher><publisher-name>Sociedade Brasileira de Dermatologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24770498</article-id><article-id pub-id-type="pmc">4008052</article-id><article-id pub-id-type="doi">10.1590/abd1806-4841.20141702</article-id><article-categories><subj-group subj-group-type="heading"><subject>Investigation</subject></subj-group></article-categories><title-group><article-title>A prospective, open, comparative study of 5% potassium hydroxide solution
versus cryotherapy in the treatment of genital warts in men<sup><xref ref-type="fn" rid="fn01">*</xref></sup>
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Camargo</surname><given-names>Caio Lamunier de Abreu</given-names></name><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Belda</surname><given-names>Walter</given-names><suffix>Junior</suffix></name></contrib><contrib contrib-type="author"><name><surname>Fagundes</surname><given-names>Luiz Jorge</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romiti</surname><given-names>Ricardo</given-names></name></contrib><aff> S&#x000e3;o Paulo University (USP) - S&#x000e3;o Paulo (SP), Brazil. </aff></contrib-group><author-notes><corresp id="c01">MAILING ADDRESS: Caio Lamunier de Abreu Camargo, Rua Oscar Freire,
1523 - Apt. 72, Pinheiros, 05409-010, S&#x000e3;o Paulo - SP, Brazil. E-mail:
<email>caiolamunier@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2014</year></pub-date><volume>89</volume><issue>2</issue><fpage>236</fpage><lpage>241</lpage><history><date date-type="received"><day>08</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>05</day><month>4</month><year>2013</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p></license></permissions><abstract><sec><title>BACKGROUND</title><p>Genital warts are caused by human papillomavirus infection and represent one of
the most common sexually transmitted diseases. Many infections are transient but
the virus may recur, persist, or become latent. To date, there is no effective
antiviral treatment to eliminate HPV infection and most therapies are aimed at the
destruction of visible lesions. Potassium hydroxide is a strong alkali that has
been shown to be safe and effective for the treatment of genital warts and
molluscum contagiosum. Cryotherapy is considered one of the most established
treatments for genital warts. No comparative trials have been reported to date on
the use of potassium hydroxide for genital warts.</p></sec><sec><title>OBJECTIVE</title><p>A prospective, open-label, randomized clinical trial was conducted to compare
topical potassium hydroxide versus cryotherapy in the treatment of genital warts
affecting immunocompetent, sexually active men.</p></sec><sec><title>METHODS</title><p>Over a period of 10 months, 48 patients were enrolled. They were randomly divided
into two groups and selected on an alternative basis for either potassium
hydroxide therapy or cryotherapy. While response to therapy did not differ
substantially between both treatment modalities, side effects such as local pain
and post-treatment hypopigmentation were considerably more prevalent in the groups
treated using cryotherapy.</p></sec><sec><title>RESULT</title><p>In our study, potassium hydroxide therapy proved to be at least as effective as
cryotherapy and offered the benefit of a better safety profile.</p></sec><sec><title>CONCLUSION</title><p>Topical 5% potassium hydroxide presents an effective, safe, and low-cost treatment
modality for genital warts in men and should be included in the spectrum of
therapies for genital warts.</p></sec></abstract><kwd-group><kwd>Clinical protocols</kwd><kwd>Comparative study</kwd><kwd>Condylomata acuminata</kwd><kwd>Cryotherapy</kwd><kwd>Genital diseases, male;</kwd><kwd>Intention to treat analysis</kwd><kwd>Male urogenital diseases</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Genital warts (GW) are the clinical result of human papillomavirus (HPV) infection, most
commonly HPV types 6 and 11.<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r03" ref-type="bibr">3</xref></sup> These viruses are sexually transmitted
and infect the skin and mucous membranes of the external genitalia, as well as the peri
and intra-anal area in both genders.<sup><xref rid="r03" ref-type="bibr">3</xref>-<xref rid="r06" ref-type="bibr">6</xref></sup> In addition, HPV types 16, 18, as well as
several others, have oncogenic potential and are involved in the development of
cervical, vulvar, penile and anal cancer.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> As a humanspecific DNA
virus, HPV is incorporated into the genome of epithelial keratinocytes. Thus,
destructive and immunomodulation topical therapies have been the standard of treatment.
Complete clearing of GW is frequently not achieved.<sup><xref rid="r08" ref-type="bibr">8</xref></sup></p><p>Treatment of warts poses a therapeutic challenge. No single therapy has been proven
effective at achieving complete remission in every patient.<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> At present,
there is no pharmacologic solution to eliminate definitely HPV from human cells. The
ideal therapy should be effective (i.e., high clearance and low recurrence rates),
non-traumatic, inexpensive and involve few local and systemic adverse effects.<sup><xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup></p><p>Potassium hydroxide (KOH) is a strong alkali that has been found to be effective, safe,
and well tolerated in the treatment of different dermatoviruses, including molluscum
contagiosum in children and genital warts in adults.<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup> This is due to its ability to dissolve keratin and
penetrate deeply the skin.<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup> Furthermore, treatment is generally well tolerated and does not
entail systemic side effects. Nonetheless, there are no comparative studies on the use
of KOH for the treatment of GW.</p><p>Cryotherapy with liquid nitrogen is one of the most established treatments for GWs and
clearance rates have ranged from between 54 and 88%.<sup><xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r20" ref-type="bibr">20</xref></sup> It has been shown to be
superior to electrodessication and podophyllin.<sup><xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref></sup> Systemic side effects
do not occur.<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup></p><p>This comparative study seeks to evaluate the efficacy and safety of topical KOH versus
cryotherapy for treatment of genital warts in sexually active men. Clearance rates,
adverse reactions, and recurrence rates after a 30-day follow-up period were
recorded.</p></sec><sec sec-type="materials|methods"><title>METHODS AND MATERIALS</title><p>This prospective, open-label clinical trial was approved by the University of S&#x000e3;o Paulo
General Hospital Institutional Review Board. The study was originally estimated based on
the mean number of new HPV cases in men at the department within a 10-month period. All
patients read and signed an informed consent form. Male patients aged over 18 with one
or more genital warts were included in the trial. Patients with urethral or peri-anal
lesions, as well as a positive status for HIV, syphilis, hepatitis B, or hepatitis C,
and diabetes or any other immunosuppression, were excluded from the study. Over a period
of 10 months, from February to December of 2009, 48 patients were enrolled. They were
randomly divided into two groups. Patients were selected on an alternative basis for
either KOH or cryotherapy.</p><p>Cryotherapy with liquid nitrogen was applied by the same physician in all patients.
Treatment cycles ranging from 5 to 20 seconds were carried out, depending on the size of
each single lesion, until a 1 mm halo was achieved. Each cycle was repeated every two
weeks until all lesions cleared, with a maximum treatment period of three months. In the
KOH group, patients were shown how to apply KOH 5% aqueous solution using a toothpick
with cotton wrap on the tip, and instructed to use the medication daily until mild
inflammation was observed. The process was repeated for three months or until complete
regression was observed. Each patient received a 10 ml flask containing a 5% KOH aqueous
solution.<sup><xref rid="r14" ref-type="bibr">14</xref></sup></p><p>In both groups, follow-up visits occurred every two weeks until all lesions cleared, or
for a maximum of 3 months. Patients were seen one month after treatment completion to
check for recurrences. At each visit, the number of lesions and local and systemic
effects, were recorded. If new lesions developed during the study, these were also
treated and included in the data.</p><p>The results were included in tables and analyzed by Chi-square and Fisher's tests. In
the results evaluation, a confidence interval (CI) of 95% was considered statistically
significant.</p></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 48 patients with GW, aged 18 to 74 (average age: 31.1 years), were included
in this study. The number of lesions ranged between 1 and 20 (average of 6.5 lesions).
Localization included the glans, foreskin, penile shaft, and pubic and scrotal area.</p><p>The KOH group included 24 patients aged 21 to 74 years (mean 32.7 years and standard
deviation of 11.0). The number of lesions ranged from 1 to 20 (mean 5.7 lesions and
standard deviation of 5.3) and the size of the lesions ranged from 1 to 30mm (mean
10.6mm and standard deviation of 7.2). Signs and symptoms of inflammation such as
erythema, edema, pain, or stinging sensations occurred one to three days after
initiating therapy. Twenty patients (83.3%) completed the study. The duration of
treatment until patients were completely wart-free ranged from 2 to 12 weeks (mean 6.9
weeks). Four patients (16.7%) did not return after the first visit and were considered
treatment failures. Seven patients (29.2%) had persistent lesions after 3 months of
treatment and were also considered treatment failures. Of the patients with complete
clearance of GW, no recurrences were observed at the one-month post-treatment follow-up
visit. At the end of the trial, 54.2% of treated patients in the KOH group were
completely wart-free without recurrences (<xref ref-type="fig" rid="f01">Figures
1</xref> to <xref ref-type="fig" rid="f04">4</xref>). Superficial erosions were
present in 50%, mild pain or stinging was reported in 16.7% and post-treatment
hypopigmentation occurred in 16.7% of treated patients.</p><fig id="f01" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Before KOH 5% treatment</p></caption><graphic xlink:href="abd-89-02-0236-g01"/></fig><fig id="f04" orientation="portrait" position="float"><label>FIGURE 4</label><caption><p>After KOH 5% treatment</p></caption><graphic xlink:href="abd-89-02-0236-g04"/></fig><p>The cryotherapy group included a total of 24 patients aged 18 to 48 years (mean 28.7
years and standard deviation of 9.6). The number of lesions ranged from 1 to 20 (mean
7.4 lesions and standard deviation of 6.0) and the size of the lesions ranged from 1 to
25mm (mean 9.6mm and standard deviation of 6.2). Twenty-two patients (91.7%) completed
the study. All patients experienced mild to moderate pain during cryotherapy
application. Signs of inflammation (erythema and edema) occurred between 24 to 48 hours
later. Duration of treatment ranged from 2 to 12 weeks (mean 9.6 weeks). Two patients
(8.3%) did not return after the first visit. Eight patients (33.3%) had persistent
lesions after 3 months of treatment, and two patients (8.3%) presented with new lesions
at the onemonth post-treatment follow-up visit. All twelve of these patients (50%) were
considered treatment failures. At the end of the trial, 50.0% of cryotherapy-treated
patients were completely wart-free without recurrences (<xref ref-type="fig" rid="f05">Figures 5</xref> and <xref ref-type="fig" rid="f06">6</xref>). Superficial erosions
were reported in 37.5% of all patients treated, mild to moderate pain in 100% and
hypopigmentation in 45.8%.</p><fig id="f05" orientation="portrait" position="float"><label>FIGURE 5</label><caption><p>Before cryotherapy treatment</p></caption><graphic xlink:href="abd-89-02-0236-g05"/></fig><fig id="f06" orientation="portrait" position="float"><label>FIGURE 6</label><caption><p>After cryotherapy treatment</p></caption><graphic xlink:href="abd-89-02-0236-g06"/></fig></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Current data suggest that visible genital warts are present in approximately 1% of
sexually active adults in the United States and an additional 15% has subclinical
infection.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> Minor breaks in the skin are thought to be important in
the establishment of HPV infection.<sup><xref rid="r02" ref-type="bibr">2</xref></sup>
The incubation period has been reported to vary between 2 weeks to 8 months.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p><p>There are no established treatments capable of eliminating HPV from human cells. HPV
vaccines based on virus-like particles can only act in a prophylactic manner. Thus,
destructive therapies and immunomodulatory agents have been the standard of treatment
for several decades.</p><p>Therapies for GW are generally recommended based on considerations of efficacy, adverse
events, cost and recurrence rates.<sup><xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r12" ref-type="bibr">12</xref></sup> Patient-applied topical treatment
modalities have included podophyllotoxin, salicylic acid, imiquimod, polyphenon E,
5-fluoracil, and KOH, among others.<sup><xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r27" ref-type="bibr">27</xref></sup> Physician-administered destructive
methods have mostly included cryotherapy, electrosurgery, intralesional bleomycin,
lasers, and diphencyprone.<sup><xref rid="r28" ref-type="bibr">28</xref>-<xref rid="r30" ref-type="bibr">30</xref></sup></p><p>The aim of this study was to compare the efficacy and safety profile of a recently
described patientapplied treatment modality, namely topical KOH solution with
physician-administered cryotherapy one of the most established and efficient therapies
for genital warts.<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r31" ref-type="bibr">31</xref></sup> In randomized controlled trials using cryotherapy for GWs, clearance
rates of 54- 88% and recurrence rates of 21-40%, have been reported with
monotherapy.<sup><xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref></sup></p><p>In this study, patients were randomized into two groups with similar characteristics,
including age, mean number and lesion size. Despite the participation of a 74-year-old
patient in the KOH group, this does not increase significantly the mean values and
standard deviations of the group. Hence, the two groups were statistically similar and
comparable in terms of age, number and size of lesions. No statistical difference in
efficacy between the KOH and the cryotherapy treated groups was observed (<xref ref-type="table" rid="t01">Table 1</xref>). There was a success rate of 65% in the
first group (KOH) compared with 54.7% in the second group (cryotherapy). The KOH group
showed a lower average for treatment duration (mean 6.9 vs. 9.6 weeks). No recurrences
were seen in the KOH group, while the cryotherapy group presented a 10% recurrence
rate.</p><table-wrap id="t01" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Comparison of treatment with 5% KOH and cryotherapy for genital warts in men</p></caption><table frame="hsides" rules="groups"><thead><tr align="left"><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">
<bold>Successfully Treated</bold>
</th><th rowspan="1" colspan="1">
<bold>Pain</bold>
</th><th colspan="2" rowspan="1">
<bold>Hypopigmentation Present</bold>
</th><th colspan="2" rowspan="1">
<bold>Erosions</bold>
</th><th rowspan="1" colspan="1">
<bold>Total number of patients</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">KOH 5%</td><td align="center" rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;</td><td rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">Cryotherapy</td><td align="center" rowspan="1" colspan="1"> 12</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1"> 22</td></tr><tr><td rowspan="1" colspan="1">
<bold>TOTAL</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>25</bold>
</td><td rowspan="1" colspan="1">
<bold>26</bold>
</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">
<bold>15</bold>
</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>42</bold>
</td></tr></tbody></table></table-wrap><p>The most significant differences between the groups concerned safety. Cryotherapy
patients complained of more pain (100% vs 16.7%; <xref ref-type="table" rid="t01">Table
1</xref>) and residual hypopigmentation (45.8% vs 16.7%; <xref ref-type="table" rid="t01">Table 1</xref>) than KOH-treated patients. KOH patients presented
superficial erosions more often than the cryotherapy group (50% vs 37.5%; <xref ref-type="table" rid="t01">Table 1</xref>). It is considered that erosion results
from the digestive properties of KOH. This side effect was entirely expected, just as
pain and hypopimentation were expected in the cryotherapy group.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Our findings regarding treatment of GW in sexually active men provide insight into a new
method of treatment, namely KOH therapy. In this study, KOH therapy proved to be at
least as effective as cryotherapy in treating GWs, with the further benefit of being
safer. However, since the sample was limited, more studies need to be conducted. Topical
5% KOH is an effective, safe, and low-cost treatment modality and should be considered
in the therapeutic arsenal against GWs in men.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>Conflict of Interest: None.</p></fn><fn fn-type="financial-disclosure"><p>Financial Support: None.</p></fn><fn fn-type="other"><p>How to cite this article: Camargo CLA, Belda Junior W, Fagundes LJ, Romiti R. A
prospective, open, comparative study of 5% potassium hydroxide solution versus
cryotherapy in the treatment of genital warts in men. An Bras Dermatol.
2014;89(2):236-40.</p></fn><fn id="fn01" fn-type="other"><label>*</label><p>Work performed at the Departamento de Dermatologia, Universidade de S&#x000e3;o Paulo (USP)
and Centro de Sa&#x000fa;de Geraldo de Paula Souza - Faculdade de Sa&#x000fa;de P&#x000fa;blica da
Universidade de S&#x000e3;o Paulo (FSP-USP) - S&#x000e3;o Paulo (SP), Brazil.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENTS</title><p>The authors thank Mrs. Sabina L&#x000e9;a Davidson Gotlieb for statistical analyses.</p></ack><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cates</surname><given-names>W Jr</given-names></name><collab>American Social Health Association Panel</collab></person-group><article-title>Estimates of the incidence and prevalence of sexually transmitted
diseases in the United States</article-title><source>Sex Transm Dis</source><year>1999</year><volume>26</volume><fpage>S2</fpage><lpage>S7</lpage><pub-id pub-id-type="pmid">10227693</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>M</given-names></name></person-group><article-title>Human papillomavirus infection</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">15504222</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsky</surname><given-names>L</given-names></name></person-group><article-title>Epidemiology of genital human papillomavirus infection</article-title><source>Am J Med</source><year>1997</year><volume>102</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9217656</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>MW</given-names></name></person-group><article-title>ABC of sexually transmitted diseases. Genital warts and molluscum
contagiosum</article-title><source>Br Med J (Clin Res Ed)</source><year>1984</year><volume>288</volume><fpage>213</fpage><lpage>215</lpage></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebner</surname><given-names>CM</given-names></name><name><surname>Laimins</surname><given-names>LA</given-names></name></person-group><article-title>Human papillomaviruses: basic mechanisms of pathogenesis and
oncogenicity</article-title><source>Rev Med Virol</source><year>2006</year><volume>16</volume><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">16287204</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handsfield</surname><given-names>HH</given-names></name></person-group><article-title>Clinical presentation and natural course of anogenital
warts</article-title><source>Am J Med</source><year>1997</year><volume>102</volume><fpage>16</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9217658</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>PT</given-names></name><name><surname>Dytoc</surname><given-names>MT</given-names></name></person-group><article-title>Therapy of external anogenital warts and molluscum contagiosum: a
literature review</article-title><source>Dermatol Ther</source><year>2004</year><volume>17</volume><fpage>68</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">14756893</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;fer</surname><given-names>H</given-names></name></person-group><article-title>Evaluation of imiquimod for the therapy of external genital and anal
warts in comparison with destructive therapies</article-title><source>Br J Dermatol</source><year>2007</year><volume>157</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">18067633</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferenczy</surname><given-names>A</given-names></name><name><surname>Mitao</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>N</given-names></name><name><surname>Silverstein</surname><given-names>SJ</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name></person-group><article-title>Latent papillomavirus and recurring genital warts</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><fpage>784</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">2993887</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>PC</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name><name><surname>Smith</surname><given-names>MH</given-names></name></person-group><article-title>The cost effectiveness of patientapplied versus provideradministered
interventions for the treatment of external genital warts</article-title><source>Am J Manag Care</source><year>1999</year><volume>5</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10345969</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Stiller</surname><given-names>M</given-names></name></person-group><article-title>Direct medical costs for surgical and medical treatment of condylomata
acuminata</article-title><source>Arch Dermatol</source><year>2001</year><volume>137</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">11255335</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>PA</given-names></name><name><surname>Tung</surname><given-names>MY</given-names></name></person-group><article-title>Human papillomavirus: burden of illness and treatment cost
considerations</article-title><source>Am J Clin Dermatol</source><year>2005</year><volume>6</volume><fpage>365</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">16343025</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romiti</surname><given-names>R</given-names></name><name><surname>Ribeiro</surname><given-names>AP</given-names></name><name><surname>Romiti</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of the effectiveness of 5% potassium hydroxide for the
treatment of molluscum contagiosum</article-title><source>Pediatr Dermatol</source><year>2000</year><volume>17</volume><fpage>495</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">11189099</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loureiro</surname><given-names>WR</given-names></name><name><surname>Ca&#x000e7;&#x000e3;o</surname><given-names>FM</given-names></name><name><surname>Belda</surname><given-names>W Jr</given-names></name><name><surname>Fagundes</surname><given-names>LJ</given-names></name><name><surname>Romiti</surname><given-names>R</given-names></name></person-group><article-title>Treatment of genital warts in men with potassium
hydroxide</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>180</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">17970810</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romiti</surname><given-names>R</given-names></name><name><surname>Ribeiro</surname><given-names>AP</given-names></name><name><surname>Grinblat</surname><given-names>BM</given-names></name><name><surname>Rivitti</surname><given-names>EA</given-names></name><name><surname>Romiti</surname><given-names>N</given-names></name></person-group><article-title>Treatment of molluscum contagiosum with potassium hydroxide: a
clinical approach in 35 children</article-title><source>Pediatr Dermatol</source><year>1999</year><volume>16</volume><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">10383783</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullah</surname><given-names>AN</given-names></name><name><surname>Walzman</surname><given-names>M</given-names></name><name><surname>Wade</surname><given-names>A</given-names></name></person-group><article-title>Treatment of external genital warts comparing cryotherapy (liquid
nitrogen) and trichloroacetic acid</article-title><source>Sex Transm Dis</source><year>1993</year><volume>20</volume><fpage>344</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">8108758</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonska</surname><given-names>S</given-names></name></person-group><article-title>Traditional therapies for the treatment of condylomata acuminata
(genital warts)</article-title><source>Australas J Dermatol</source><year>1998</year><volume>39</volume><fpage>S2</fpage><lpage>S4</lpage><pub-id pub-id-type="pmid">9842092</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>A</given-names></name><name><surname>Bhatia</surname><given-names>NN</given-names></name><name><surname>Broen</surname><given-names>EM</given-names></name></person-group><article-title>Cryotherapy for treatment of genital condylomata during
pregnancy</article-title><source>J Reprod Med</source><year>1984</year><volume>29</volume><fpage>432</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">6481698</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Black-Noller</surname><given-names>G</given-names></name><name><surname>Riendeau</surname><given-names>LA</given-names></name><name><surname>Monti</surname><given-names>KL</given-names></name></person-group><article-title>The use of EMLA cream and 1% lidocaine infiltration in men for relief
of pain associated with the removal of genital warts by
cryotherapy</article-title><source>J Am Acad Dermatol</source><year>1997</year><volume>37</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">9216530</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariq</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>JD</given-names></name></person-group><article-title>Viral sexually transmitted infections: current management
strategies</article-title><source>J Clin Pharm Ther</source><year>1999</year><volume>24</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">10651973</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetmore</surname><given-names>SJ</given-names></name></person-group><article-title>Cryosurgery for common skin lesions. Treatment in family physicians'
offices</article-title><source>Can Fam Physician</source><year>1999</year><volume>45</volume><fpage>964</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">10216795</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>AK</given-names></name></person-group><article-title>Cryosurgery of genital warts in cases in which podophyllin treatment
failed or was contraindicated</article-title><source>Br J Vener Dis</source><year>1977</year><volume>53</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">843897</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>PD</given-names></name><name><surname>Langlet</surname><given-names>F</given-names></name><name><surname>Thin</surname><given-names>RN</given-names></name></person-group><article-title>Cryotherapy versus electrocautery in the treatment of genital
warts</article-title><source>Br J Vener Dis</source><year>1981</year><volume>57</volume><fpage>273</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">7272706</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashi</surname><given-names>SA</given-names></name></person-group><article-title>Cryotherapy versus podophyllin in the treatment of genital
warts</article-title><source>Int J Dermatol</source><year>1985</year><volume>24</volume><fpage>535</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">4066094</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>A</given-names></name><name><surname>Brinkeborn</surname><given-names>RM</given-names></name><name><surname>Siboulet</surname><given-names>A</given-names></name></person-group><article-title>Topical treatment of genital warts in men, an open study of
podophyllotoxin cream compared with solution</article-title><source>Genitourin Med</source><year>1995</year><volume>71</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">8566979</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockfleth</surname><given-names>E</given-names></name><name><surname>Beti</surname><given-names>H</given-names></name><name><surname>Orasan</surname><given-names>R</given-names></name><name><surname>Grigorian</surname><given-names>F</given-names></name><name><surname>Mescheder</surname><given-names>A</given-names></name><name><surname>Tawfik</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Topical Polyphenon E in the treatment of external genital and perianal
warts: a randomized controlled trial</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">18363746</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djawari</surname><given-names>D</given-names></name></person-group><article-title>5-Fluorouracil treatment of condylomata acuminata</article-title><source>Z Hautkr</source><year>1986</year><volume>61</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">3705667</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weismann</surname><given-names>K</given-names></name><name><surname>Kassis</surname><given-names>V</given-names></name></person-group><article-title>Treatment of condyloma acuminatum with 0.5% 5-fluorouracil-solution, A
double-blind clinical trial</article-title><source>Z Hautkr</source><year>1982</year><volume>57</volume><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">7048776</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilson</surname><given-names>RJ</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Maw</surname><given-names>R</given-names></name><name><surname>Rowen</surname><given-names>D</given-names></name><name><surname>Sonnex</surname><given-names>C</given-names></name><name><surname>Lacey</surname><given-names>CJ</given-names></name></person-group><article-title>A multicentre, randomised, double-blind, placebo controlled study of
cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external
anogenital warts</article-title><source>Sex Transm Infect</source><year>2009</year><volume>85</volume><fpage>514</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">19700413</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaza</surname><given-names>M</given-names></name><name><surname>Grassi</surname><given-names>C</given-names></name><name><surname>Mardjonovic</surname><given-names>A</given-names></name><name><surname>Valli</surname><given-names>E</given-names></name><name><surname>Farn&#x000e9;</surname><given-names>C</given-names></name><name><surname>Romanini</surname><given-names>C</given-names></name></person-group><article-title>The use of electrosurgery in the treatment of extra-cervical genital
condylomatosis</article-title><source>Minerva Ginecol</source><year>1998</year><volume>50</volume><fpage>367</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">9842204</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>AL</given-names></name><name><surname>Siegfried</surname><given-names>EC</given-names></name></person-group><article-title>Management of warts and molluscum in adolescents</article-title><source>Adolesc Med</source><year>2001</year><volume>12</volume><fpage>229</fpage><lpage>242</lpage><page-range>vi, 229-42</page-range></element-citation></ref></ref-list></back><floats-group><fig id="f02" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Before KOH 5% treatment</p></caption><graphic xlink:href="abd-89-02-0236-g02"/></fig><fig id="f03" orientation="portrait" position="float"><label>FIGURE 3</label><caption><p>After KOH 5% treatment</p></caption><graphic xlink:href="abd-89-02-0236-g03"/></fig></floats-group></article>